A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Dose of SYH2082 Injection in Healthy Participants
Latest Information Update: 23 Apr 2026
At a glance
- Drugs SYH 2082 (Primary)
- Indications Obesity
- Focus Adverse reactions
- Sponsors CSPC ZhongQi Pharmaceutical Technology
Most Recent Events
- 23 Apr 2026 New trial record